ChemMedChem 2018-04-16

Design, Synthesis, and Biological Evaluation of Bivalent Ligands Targeting Dopamine D2‐Like Receptors and the μ‐Opioid Receptor

Mingcheng Qian; Lakshmi Vasudevan; Jelle Huysentruyt; Martijn D. P. Risseeuw; Christophe Stove; Patrick M. L. Vanderheyden; Kathleen Van Craenenbroeck; Serge Van Calenbergh

Index: 10.1002/cmdc.201700787

Full Text: HTML

Abstract

Currently, there is mounting evidence that intermolecular receptor–receptor interactions may result in altered receptor recognition, pharmacology and signaling. Heterobivalent ligands have been proven useful as molecular probes for confirming and targeting heteromeric receptors. This report describes the design and synthesis of novel heterobivalent ligands for dopamine D2‐like receptors (D2‐likeR) and the μ‐opioid receptor (μOR) and their evaluation using ligand binding and functional assays. Interestingly, we identified a potent bivalent ligand that contains a short 18‐atom linker and combines good potency with high efficacy both in β‐arrestin 2 recruitment for μOR and MAPK‐P for D4R. Furthermore, this compound was characterized by a biphasic competition binding curve for the D4R–μOR heterodimer, indicative of a bivalent binding mode. As this compound possibly bridges the D4R–μOR heterodimer, it could be used as a pharmacological tool to further investigate the interactions of D4R and μOR.

Latest Articles:

Identifying Small‐Molecule Binding Sites for Epigenetic Proteins at Domain–Domain Interfaces

2018-04-17

[10.1002/cmdc.201800030]

Fluorinated GluN2B Receptor Antagonists with a 3‐Benzazepine Scaffold Designed for PET Studies

2018-04-17

[10.1002/cmdc.201700819]

Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone‐Based Cannabinoid Receptor Type 2 Ligands

2018-04-16

[10.1002/cmdc.201800152]

Discovery of Benzimidazole–Quinolone Hybrids as New Cleaving Agents toward Drug‐Resistant Pseudomonas aeruginosa DNA

2018-04-16

[10.1002/cmdc.201700739]

Transthyretin Mimetics as Anti‐β‐Amyloid Agents: A Comparison of Peptide and Protein Approaches

2018-04-16

[10.1002/cmdc.201800031]

More Articles...